Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imneskibart
- Development stage
- Phase 2
- Lead developer
- Aulos Bioscience, Inc.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Imneskibart (AU-007) is a human monoclonal antibody designed using artificial intelligence. It targets interleukin-2 (IL-2) by binding to the portion of IL-2 that interacts with the CD25 receptor subunit, preventing regulatory T cell expansion while allowing IL-2 to bind to CD8 effector T cells, thereby promoting tumor killing. It is being developed for solid tumors, including melanoma and non-small cell lung cancer, and has shown efficacy in patients refractory to checkpoint inhibitors.
- Brand names
- imneskibart
- Other names
- AU-007AU007AU 007BD-8BD8BD 8BDG8BDG-8BDG 8
02
Targets
IL-2 (Interleukin 2)IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on imneskibart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imneskibart.